More than 20 patients say the quality of life was ruined when he was unnecessarily given a highly toxic cancer drug, joining the NHS Trust.
Some people were determined tempozolomide – which should usually be used for only six months – university hospitals covantry and Warvikshire NHS Trust for more than a decade during treatment.
They say that overproibing left him with side-effects including secondary cancer and crippling fatigue.
Earlier this year Care Quality Commission Was looking at at least 14 cases, but lawyers say that they are emerging more at all times.
An investigation by the lawyers of the lawyers found that, in the last two decades, under the care of Professor Ian Brown, many patients with brain and spinal tumors were regularly exposed for prolonged and in some cases for “unnecessary” use. Chemotherapy The drug, which has severe side effects including excessive fatigue, confusion, disease and seizures.
Time -term tempozolomide was allegedly run in contrast to medical and scientific guidelines. The standard NHS process is to use the drug in six months, and the drug manufacturer recommends that it be used up to 12 months.
One person stated that he was determined for more than the necessary for about two years, as a result of excessive fatigue and low mood suffering.
In her twenty -nine condition, a woman said that she was wrong with cancer, being unnecessarily receiving the drug unnecessarily.
Some patients are now treated for secondary cancer, allegedly associated with extreme use of tempozolomide, claims lawyers.
Others claimed that its prolonged use left them unable to pursue career’s ambitions and normal day-to-day activities as chemotherapy was weakening, with prolonged recovery time. Some reported the loss of fertility or abnormal blood test results.
The legal team says that data suggests that the trust on the medicine of £ 3.6m from 2009 to 2024 is 10 times compared to other NHS oncology departments.
Advocates are now calling for an extended patient safety review and independent investigation, especially returning to the treatment received by patients under Professor Brown Dating.
The trust is conducting an internal patient safety review, covering from 2017 to 2023, when Professor Brown retired.
A patient who identified only as Michael received 22 cycles in addition to the tempozolomide in the trust, despite his scan being stable.
Professors were not present during brown consultation, and Michael said that he was always seen by a clinical nurse expert.
After suffering from excessive fatigue and low mood, he learned through reports of misconduct from the trust, according to his lawyers – that he should not have treated for so long.
Another patient, who is identified only as Becky, says that he received at least 100 cycles of the drug unnecessarily after he was unnecessarily diagnosed with brain tumors.
Fona Tinsley, the head of medical negligence in Breets, said: “The range of this scam, and it has a physical and mental effect on patients with Professor Brown, cannot be underestimated.”
He said: “We are confident that there are many more patients who have not come forward yet and some people who can be unhappy can die.
“While we welcome the ongoing investigation General medical council And Royal college of physicianWe believe that a complete independent investigation is necessary – in which its review of the trust is expanded until 2006 – not only to ensure justice for the victims, but also the procedures to identify and prevent such failures. ,
A trust spokesman told Independent: “We have made extensive reviews from all the persons and talked to all those who were receiving TMZ treatment at the end of 2023 to ensure proper support and care plans.
“A glioblastoma is an invasive brain tumor with less than two percent of patients living for more than 10 years and carry all the methods of treatment-Argentraphy, chemotherapy and radiotherapy-complexities and risk of side-effects.
“The National Institute for Health and Care Excellence (NICE) guidelines believe that doctors can use a professional decision suitable for personal conditions when offering treatment to patients.
“We have commissioned the Royal College of Physicians to freely review a representative colleague of patients receiving more than 12 cycles of assistant TMZ between 2017 and 2023.
“As this process continues, it would be unfair to comment further at this stage.”
It is understood that the CQC Inspector is in touch with the trust to understand the details, and take assurance that the patients are not at risk. The regulator will review more information to judge whether it needs to be included.
